MedTrace Logo

Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects

NCT01723748 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-04-05

No results posted yet for this study

Summary

The treatment with SA still leaves some questions unanswered. Firstly, SA treatment often results in a concomitant suppression of the insulin secretion, which might lead to clinically significant glucose intolerance. Secondly, the traditional evaluation of disease activity by measuring circulating levels of GH and total IGF-I is not reliable enough

Hypotheses: Treatment of acromegaly with SA versus surgery alone is associated with:

* Glucose intolerance despite normalized insulin sensitivity
* Modified peripheral GH activity in peripheral target organs assessed on molecular endpoints

Conditions

Interventions

DRUG

genotropin

iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jens Otto L Joergensen, professor · Aarhus University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01723748 on ClinicalTrials.gov